SynthesisOncotarget2017
Association between MMP2-1306 C/T polymorphism and prostate cancer susceptibility: a meta-analysis based on 3906 subjects.
Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current evidence on the relationships among five polymorphisms in the matrix metalloproteinases genes and prostate cancer risk.Scientific reports · 2024Pooled it
- Activities and polymorphisms of MMP-2 and MMP-9, smoking, diabetes and risk of prostate cancer.Molecular biology reports · 2020Article
- Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer.Digestive diseases and sciences · 2020Article
- KLF4 overexpression decreases the viability, invasion and migration of papillary thyroid cancer cells.Experimental and therapeutic medicine · 2019Article
- Gendermetrics of cancer research: results from a global analysis on prostate cancer.Oncotarget · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous investigations have addressed the correlation between MMP2-1306C/T polymorphism and prostate cancer (PCa) susceptibility. However, these conclusions were controversial. Thus, we conducted this current meta-analysis based on six studies from PubMed, Embase, Cochrane Library, China Biology Medicine disc (CBM), China National Knowledge Infrastructure (CNKI) up to October 21st, 2016. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to evaluate the strength of the correlations. Additionally, different subgroup analyses and publication bias tests were performed. Eventually, six previous investigations consisted of 1920 cases and 1986 controls were identified and involved in this meta-analysis. Consequently, our evidence indicates a certain association between MMP2-1306C/T polymorphism and PCa risk among overall population (T vs C: OR = 1.12, 95% CI = 1.00-1.24, P = 0.040; TT+CT vs CC: OR = 1.16, 95% CI = 1.02-1.32, P = 0.026; respectively), as well as the subgroups of Asian population (T vs C: OR=1.48, 95% CI=1.13-1.94, P=0.004; TT+CT vs CC: OR = 1.66, 95% CI = 1.21-2.28, P = 0.002; respectively) and PCR-RFLP genotyped method (T vs C: OR = 1.58, 95% CI = 1.19-2.10, P = 0.001; TT+CT vs CC: OR = 1.71, 95% CI = 1.23-2.38, P = 0.001; respectively). However, no association was detected in MMP2-1306C/T polymorphism with Gleason grading or pathological stage of PCa. Our study indicates MMP2-1306 C/T polymorphism might increase PCa risk, particularly for Asian population. However, future studies comprising large cohort size from multicenter are required to confirm our conclusions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.